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Transcriptional dysregulation by mutant huntingtin (Htt) protein has been implicated in the pathogenesis of Huntington’s disease (HD).
We find that cultured cells expressing mutant Htt and striatal cells from HD transgenic mice have elevated nuclear factor-B (NF-B)
activity. Furthermore, NF-B is concentrated in the nucleus of neurons in the brains of HD transgenic mice. In inducible PC12 cells and
in HD transgenic mice, mutant Htt activates the IB kinase complex (IKK), a key regulator of NF-B. Activation of IKK is likely mediated
by direct interaction with mutant Htt, because the expanded polyglutamine stretch and adjacent proline-rich motifs in mutant Htt
interact with IKK, a regulatory subunit of IKK. Activation of IKK may also influence the toxicity of mutant Htt, because expression of
IKK promotes aggregation and nuclear localization of mutant Htt exon-1. Moreover, in acute striatal slice cultures, inhibition of IKK
activity with an N-terminally truncated form of IKK blocks mutant Htt-induced toxicity in medium-sized spiny neurons (MSNs). In
addition, blocking degradation of NF-B inhibitors with a dominant-negative ubiquitin ligase -transducin repeat-containing protein
also reduces the toxicity of mutant Htt in MSNs. Therefore, aberrant NF-B activation may contribute to the neurodegeneration induced
by mutant Htt.
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Introduction
Huntington’s disease (HD) is a neurodegenerative disorder
caused by expansion of polyglutamine (polyQ) in exon-1 (HDx1)
of huntingtin (Htt) (Huntington’s Disease Collaborative Re-
search Group, 1993). Neuronal death in HD has been variously
attributed to polyQ toxicity, activation of caspases, interference
with transcription, and sequestration of cellular proteins (Li,
1999; Tobin and Signer, 2000; Wanker, 2000; Zoghbi and Orr,
2000). Several proteins that interact with HDx1 have been iden-
tified (Cattaneo et al., 2001), and although the function of some
of these proteins in the etiology of HD is unclear, the transcrip-
tional coactivator cAMP response element (CRE)-binding pro-
tein (CBP), as well as proteins containing WW domains, have
been implicated in HD pathology (Passani et al., 2000; Steffan et
al., 2000; Nucifora et al., 2001). Htt binding blocks CBP-
mediated gene expression, and histone deacetylase inhibitors re-
duce polyglutamine-induced cell death in Drosophila (Steffan et
al., 2001). Conversely, CRE-mediated gene expression, which re-
quires CBP, is enhanced in HD transgenic mice (Obrietan and
Hoyt, 2004). CBP participates in many signaling pathways, in-
cluding NF-B (Chen et al., 2002; Zhong et al., 2002). Conse-
quently, mutant Htt dysregulation of CBP can influence nuclear
factor-B (NF-B)-mediated gene expression.
NF-B is sequestered in the cytoplasm by a family of inhibi-
tory proteins (IBs) (Ghosh et al., 1998). IBs are phosphory-
lated by a signal-activated kinase complex known as I-B kinase
(IKK) (Ghosh and Karin, 2002). This complex contains two cat-
alytic subunits, IKK and IKK, and a regulatory module, IKK
(Karin and Lin, 2002). Phosphorylated IBs are ubiquitinated by
an F-box E3-ligase, -transducin repeat-containing protein (-
TrCP) (Spencer et al., 1999) and subsequently degraded by pro-
teosomes. Liberated NF-B can bind DNA and promote gene
expression (Pahl, 1999).
In the nervous system, cytokines, neurotrophic factors, neu-
rotransmitters, injury, seizure, and proteins implicated in neuro-
degenerative disorders can all activate the NF-B pathway (Matt-
son and Camandola, 2001). Injection of 3-nitropropionic acid
(3NP) and kainate into the striatum, which mimics pathology
caused by mutant Htt, results in activation of NF-B and expres-
sion of the proapoptotic gene products, myc and p53 (Qin et al.,
1999). On the other hand, injection of 3NP into the striatum of
mice lacking the p50 subunit of NF-B results in diminished
NF-B activity and increased cell death (Mattson and Caman-
dola, 2001).
Akt/protein kinase B, an activator of IKK, has been shown to
phosphorylate mutant Htt and appears to have a neuroprotective
effect (Datta et al., 1999; Humbert et al., 2002). Furthermore,
striatal cells from HD knock-in (KI) mice display elevated Akt
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activity; however, expression of mutant Htt in these cells is not
toxic (Gines et al., 2003). Akt also phosphorylates ataxin-1, which
binds to 14-3-3 protein and enhances its stability, aggregation,
and neurotoxicity (Chen et al., 2003; Emamian et al., 2003).
Thus, as a major integrator of cell signaling, NF-B may regulate
the pathogenesis of polyglutamine-induced neurodegeneration.
Here we show that mutant Htt binds IKK, activates the IKK
complex, and elevates NF-B-dependent gene expression. Fur-
thermore, HDx1-mediated toxicity is significantly reduced by
genetic inhibition of IKK and NF-B activity.
Materials and Methods
Cells and transgenic animals. PC12 cells, which express wild-type
(WT) HDx1-enhanced green fluorescent protein (EGFP) with 25 glu-
tamine repeats (25Qs) or mutant HDx1-EGFP with 103Qs in re-
sponse to ecdysone, were kindly provided by Dr. E. Schweitzer (Uni-
versity of California Los Angeles). These cells were cultured on a
collagen I substrate (Fisher Scientific, Tustin, CA) in DMEM with 5%
horse serum, 5% fetal bovine serum, 2 mM glutamine, and standard
penicillin–streptomycin antibiotics. Immortalized striatal cells from
WT and HD KI mice, provided by Dr. M. E. MacDonald (Massachu-
setts General Hospital, Boston, MA), were cultured as described
(Gines et al., 2003). Human embryonic kidney (HEK)-293 cells were
cultured as described previously (Khoshnan et al., 2002). The HD
transgenic mouse line R6/2 and a knock-in line, in which a 155 poly-
glutamine stretch was inserted in HDx1 of mouse Htt, have been
described (Davies et al., 1997; Lin et al., 2001). Colonies were estab-
lished and maintained in our animal facility.
Gene reporter assays and transfections. The pNF-B-luciferase with five
enhancer elements and the control plasmid without NF-B binding sites,
pCIS-CK-luciferase, were used for gene reporter assays (Stratagene, La
Jolla, CA). To normalize for transfection efficiency between samples, a
-galactosidase (-gal) construct expressed from the elongation factor
(EF)-1 promoter (Invitrogen, Carlsbad, CA) was included in all gene
reporter assays. PC12 cells were transfected with control or NF-B-
luciferase plasmids using lipofectamine-plus. On the following day, cells
were left untreated or stimulated for 8 hr with 1 g/ml ecdysone to
induce expression of HDx1. Mock treatment or NGF (Sigma, St. Louis,
MO) was added (50 ng/ml) and incubated for an additional 6 hr. Cells
were suspended in lysis buffer on ice for 10 min and cleared by centrifu-
gation. Luciferase activity was measured by addition of the substrate
(Promega, Madison, WI) to equal amounts of protein from each sample.
Striatal cells from WT and HD KI mice were transfected with an NF-B
reporter plus -gal and anti-polyQ (MW2) or anti-polyproline [anti-
polyP (MW7)] recombinant intrabodies (Khoshnan et al., 2002). On the
following day, cells were starved for 2 hr and treated with 5 ng/ml recom-
binant interleukin (IL)-1 (R & D Systems, Minneapolis, MN) and in-
cubated for an additional 6 hr. Cells were harvested and cleared lysate was
used to measure luciferase as described above. All gene reporter assays
were corrected for transfection efficiency by normalizing the units of
-gal in the extracts, using the-gal assay (Invitrogen).-gal values from
the samples were divided by the -gal value from control, 25polyQ,
noninduced PC12 cells (no expression of HDx1) and multiplied by each
corresponding luciferase reading. For striatal cells, -gal values were
divided by the value obtained for WT cells without any treatment. Results
are shown as relative luciferase units and are representative of at least
three independent experiments. Data points are the average of triplicate
measurements.
To examine the effects of deleted F-box (F)-TrCP [obtained from
Dr. R. Deshaies (California Institute of Technology) and originally pro-
vided by Spencer et al. (1999)] and deleted N terminus (DN)-IKK on
mutant HDx1-induced NF-B, PC12 cells were transfected with F-
TrCP or DN-IKK plus -gal and NF-B reporter in six-well plates.
Induction of HDx1 with ecdysone and NGF treatment was as described
above. Equal amounts of each sample were used to measure luciferase
activity. Binding of NF-B to its consensus oligonucleotide site was as-
sayed in striatal neurons with the BD TransFactor Kit specific for the p65
subunit following the manufacturer’s instructions (BD Biosciences,
Mountain View, CA). Briefly, striatal cell lines from WT and HD KI mice
were starved for 2 hr and treated with 5 ng/ml IL-1 for 15 or 30 min.
Nuclear extracts were obtained using commercial reagents (BD Bio-
sciences). Protein concentration was determined by the BCA method
(Pierce, Rockford, IL). Equal amounts of each nuclear fraction were
added to wells coated with an NF-B consensus or mutated control
oligonucleotide and incubated at room temperature for 1 hr. Wells were
washed extensively and incubated with primary rabbit antibody specific
for the p65 subunit of NF-B. Bound p65 was detected with a goat
anti-rabbit antibody conjugated to horseradish peroxidase. After addi-
tion of the substrate, 3,3-5,5-tetramethylybenzidine, color development
was measured at 655 nm using an ELISA plate reader. Samples were done
in triplicate, and the results shown are representative of three indepen-
dent experiments.
Transfection of HEK-293 cells with mutant HDx1-EGFP alone (Ka-
zantsev et al., 1999) or with one of the following HA-tagged constructs,
full-length (F), DN, and deleted C terminus (DC) of IKK (provided by
Dr. E. Zandi, University of Southern California) (Rothwarf et al., 1998)
or F-TrCP, was done using lipofectamine-plus reagents (Invitrogen).
For histochemistry, cultured cells were fixed in 4% paraformaldehyde for
30 min, permeabilized with 70% methanol for 1 hr, and washed with
PBS. Cells were stained with anti-HA tag for IKK or anti-myc for F-
TrCP (Cell Signaling, Beverly, MA) followed by a goat anti-mouse an-
tibody conjugated to Alexa 594 (Molecular Probes, Eugene, OR). Toto-3,
a dimeric cyanine, was used to stain nuclei (Molecular Probes). Cells
were washed in PBS, mounted on microscope slides, and examined
with a confocal microscope. Mutant HDx1 toxicity was assessed by
counting the number of condensed GFP-positive bodies, which are
remnants of terminal deoxynucleotidyl transferase-mediated biotin-
ylated UTP nick end labeling (TUNEL)-positive (TUNEL) cells
(Khoshnan et al., 2002), using a florescence microscope. For TUNEL
staining, transfected cells grown on coverslips were air dried and fixed
16 hr after transfection as above and permeabilized in ethanol/acetic
acid (2:1). Apoptotic cells were labeled with terminal deoxynucleoti-
dyl transferase using digoxigenin-labeled nucleotides and detected by
anti-digoxigenin antibody and rhodamine-conjugated secondary ac-
cording to the instructions provided by the manufacturer (Chemicon,
Temecula, CA).
Immunohistochemistry of tissue sections. Brains were taken from
paraformaldehyde-fixed WT and R6/2 HD transgenic mice, and cryosec-
tions were permeabilized in 70% methanol for 1 hr at20. After block-
ing in 3% BSA and 10% normal goat serum, slides were incubated with
anti-p65 (Santa Cruz Biotechnology, Santa Cruz, CA) and the neuronal
marker anti-neuronal-specific nuclear protein (NeuN) antibodies
(Chemicon). p65-positive cells were detected with a goat anti-rabbit sec-
ondary antibody conjugated to FITC and goat anti-mouse Alexa Fluor
594 (Molecular Probes). Toto-3 was used to stain nuclei. Sections were
examined with a confocal microscope. Total neurons from 16 coronal
sections containing cortical and striatal areas of four animals each of WT
and HD mice were quantified, and the average percentage of cells with
nuclear p65 is presented.
Protein–protein interaction. In vitro binding of IKK to mutant HDx1
was performed using glutathione S-transferase (GST)-pull down assays.
GST-HDx1 with 20 or 51 polyQs, with and without polyproline domains,
was obtained from Dr. E. Wanker (Max Plank Institute, Berlin, Ger-
many). These constructs were expressed in Escherichia coli and purified
with glutathione beads (Amersham Biosciences, Piscataway, NJ) accord-
ing to manufacturer’s instructions. IKK constructs were transcribed
and translated in rabbit reticulocytes in the presence of [ 35S]methionine
(Promega). Briefly, 5 g of GST-HDx1 bound to beads was incubated
with 10 l of each labeled in vitro-translated IKK product in 500 l of
Tris-based buffer containing 10% glycerol and 5 mM DTT and rocked at
room temperature for 2 hr. Beads were washed five times in the same
buffer. Bound IKK was examined by SDS-PAGE, followed by autora-
diography. Recombinant anti-HDx1 intrabodies (Khoshnan et al., 2002)
were expressed and examined similarly for binding to GST-HDx1. For
competition assays, 10-fold excess in vitro-translated intrabodies were
added to GST-HDx1 plus DC-IKK and processed as above.
For coimmunoprecipitation studies, PC12 cells or striatal tissue of WT
8000 • J. Neurosci., September 15, 2004 • 24(37):7999 – 8008 Khoshnan et al. • IKK Activation and Mutant Huntingtin Neurotoxicity
and HD transgenic mice was lysed by sonication in buffer A (50 mM
HEPES, pH 7.6, 250 mM NaCl, 1% Triton X-100, 2 mM MgCl2, 2 mM
DTT, 1 mM Na3VO4, and 20 M -glycerophosphate) and a mixture of
protease inhibitors (Boehringer Mannheim, Mannheim, Germany).
Equal amounts of cleared extracts from each sample were incubated with
a rabbit anti-IKK (Santa Cruz Biotechnology) coupled to protein-A
beads and rocked for 3 hr at 4°C. Cells were washed five times with buffer
A. Immune complexes were examined by SDS-PAGE followed by West-
ern blotting with monoclonal antibodies targeting Htt (Ko et al., 2001),
as described in the figure legends.
Immune complex kinase assays. To measure IKK activity, immunopre-
cipitated IKK complexes were examined for the ability to phosphorylate
GST-IB in vitro. The construct for the N-terminal 61 amino acids of
GST-IB, which contains the IKK phosphorylation sites (provided by
Dr. W. Greene, University of California San Francisco), was expressed in
E. coli and purified on glutathione beads as described in the manufactur-
er’s instructions (Amersham Biosciences). To obtain IKK complexes,
equal amounts of cleared striatal extracts from WT and HD animals, or
from PC12 cells induced to express WT or mutant HDx1-EGFP (all in
buffer A), were incubated with a mouse anti-IKK antibody (Santa Cruz
Biotechnology) coupled to protein-A beads and rocked for 3 hr at 4°C.
Beads were washed five times in buffer B (50 mM HEPES, pH 7.6, 250 mM
NaCl, 1 M urea, 0.1% Nonidet P-40, 6 mM EDTA, 6 mMEGTA, 1 mM DTT
with 20 M -glycerophosphate) and a mixture of protease inhibitors
and equilibrated in kinase buffer (20 mM HEPES, pH 7.6, 2 mM MgCl2, 2
mM MnCl2, 10 M ATP, 10 mM glycerophosphate, 10 mM NaF, 300 M
Na3VO4, 1 mM dithiothreitol DTT). IKK activity was evaluated in vitro
with 1 g of purified GST-IB (N-terminal 61 amino acids) in the
presence of 10 Ci of [ 32P]-ATP for 30 min at 30°C. Products were
examined by SDS-PAGE followed by autoradiography. Duplicate sam-
ples were examined by Western blotting using a rabbit anti-IKK anti-
body (Santa Cruz Biotechnology).
Brain slice preparation. All animal experiments were performed in ac-
cordance with the Institutional Animal Care and Use Committee and
Duke University Medical Center Animal Guidelines. Postnatal day 7 (P7)
CD Sprague Dawley rats (Charles River Laboratory, Raleigh, NC) were
decapitated, and the brains were surgically removed and placed in ice-
cold Neurobasal medium (Invitrogen). The tissue was fixed to a chilled,
stainless steel Vibratome stage using cyanoacrylate glue (Krazy-Glue)
and covered with Neurobasal medium. Coronal brain slices (250 m
thick) were cut by Vibratome (VT1000S; Leica, Nussloch, Germany) as
described previously (Edgerton and Reinhart, 2003). Brain slices were
kept at 37°C in 5.0% CO2 for 1 hr.
Biolistic transfection. Gold particles (1.6 m gold microcarriers; Bio-
Rad, Hercules, CA) were used as DNA carriers for transfection as de-
scribed previously (Lo et al., 1994). Briefly, gold particles were sonicated
in 0.05 M spermidine in the presence of plasmid DNA. The gold–DNA
mixture was washed three times in 100% ethanol before being loaded
into Helios plastic cartridges (Bio-Rad) according to manufacturer’s in-
structions. Slices were transfected using a Bio-Rad Helios gun with a cyan
fluorescent protein (CFP)-tagged Htt fragment, together with yellow
fluorescent protein (YFP) as a morphometric marker. In a number of
experiments, one of the IKK constructs was also cotransfected with the
Htt-construct and YFP. CFP-tagged Htt fragments were exon-1
N-terminal fragments containing either a short-Q (Q23) or a long-Q
(Q148) polyQ domain.
Brain slice neurodegeneration assay. For each condition, transfections
were performed on 12 brain slices per experiment. Protein expression
and neurodegeneration (loss of processes, shriveling of the soma) were
assayed 2–7 d after transfection using a Leica fluorescence microscope
with appropriate filters for YFP and CFP. The total area of the striatum
was identified, and transfected MSNs were identified by their morphol-
ogy. CFP fluorescence was used to determine expression of Htt fragments
and their aggregation into macro-inclusions. Each experiment involved
3–12 transfected brain slices per condition, and the data are means from
six independent experiments for each condition.
Results
Mutant Htt activates the NF-B pathway
We first used PC12 cells that express WT (25Q) or mutant
(103Q) HDx1 in response to ecdysone (Fig. 1A). These cells were
transfected with a reporter construct containing NF-B enhancer
element fused to luciferase. The inducible nature of HDx1 ex-
pression allows the examination of soluble mutant HDx1 func-
tion, before macro-aggregates become visible. Induction of mu-
tant HDx1 expression increases transcription from the NF-B-
dependent promoter approximately fivefold over that of
noninduced cells, whereas WT HDx1 has minimal effect (Fig.
1A). These results are consistent with a recent report demonstrat-
ing upregulation of NF-B expression by mutant HDx1 in induc-
ible PC12 cells (Sugars et al., 2004). To examine whether mutant
HDx1 also influences signal-induced NF-B activation, we used
NGF, which is known to activate NF-B in PC12 cells (Foehr et
al., 2000). Mutant (but not WT) HDx1 strongly enhances NGF-
Figure 1. Mutant Htt activates NF-B-dependent gene expression. A, PC12 cells transfected
with an NF-B reporter plasmid were induced to express a 25 or 103 polyQ-containing HDx1-
EGFP. NGF was added 8 hr after Htt induction, and the cells were incubated for an additional 6 hr.
Cleared lysates were assayed for luciferase activity to assess NF-B-dependent gene expres-
sion. The luciferase values were normalized for transfection efficiency using the-gal reporter
gene under transcriptional control of the EF-1 promoter. -gal values from samples were
divided by the-gal values from control, 25polyQ, noninduced HDx1 (no expression of HDx1)
and multiplied by the corresponding luciferase readings. Results are shown as relative luciferase
units and are representative of at least three independent experiments, and data points are the
average of triplicate measurements. The Western blot at the bottom of A shows the level of
soluble HDx1 detected using an anti-Htt antibody. The same blots were probed with anti-
tubulin to show equivalent loading in each lane. B, Expression of WT or mutant HDx1 does not
influence luciferase expression from the control plasmid, which lacks an NF-B enhancer ele-
ment. The experiment was done as in A, using a plasmid reporter without the NF-B enhancers.
Luciferase units were100-fold less than the activity observed with the NF-B reporter. C,
NF-B activation by mutant Htt includes degradation of IB. PC12 cells were treated with
ecdysone to induce HDx1 for the indicated time and examined by Western blotting with anti-
IB antibody. The same membrane was stained with anti-tubulin antibody for loading accu-
racy. D, Full-length mutant Htt enhances IL-1-mediated NF-B activation. Striatal cells from
WT and HD KI mice were transfected with NF-B or the control reporter and the indicated
plasmids. Transfected cells were starved on the following day for 2 hr and treated with 5 ng/ml
IL-1 for an additional 6 hr. Luciferase activity was measured in equal amounts of cleared lysate
from each sample and normalized to-gal units from WT striatal cells without IL-1.
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induced NF-B-dependent gene expression (Fig. 1A). Because
mutant Htt has been shown to variably influence gene expression
from different promoters, we performed the same experiments
with a control plasmid that lacks an NF-B enhancer element.
Expression of WT or mutant HDx1 does not influence luciferase
expression from the control plasmid (Fig. 1B), suggesting that
the elevated NF-B values in Figure 1A are mediated by mutant
HDx1 expression. Under the conditions tested, most of the HDx1
remains in the detergent-soluble fraction and is detectable by
Western blotting (Fig. 1A); however, the NF-B activity dimin-
ishes as mutant HDx1 accumulates and aggregates (data not
shown). Thus, soluble mutant HDx1 activates endogenous, and
augments NGF-induced, NF-B-dependent gene expression.
Moreover, expression of mutant HDx1 promotes degradation of
the inhibitory protein IB, a hallmark of NF-B activation.
Levels of IB drop significantly by 3 hr and return to normal by
7 hr after induction (Fig. 1C). These data confirm the gene re-
porter assay results and suggest that mutant Htt-induced NF-B
is mediated by degradation of IB.
To examine whether full-length mutant Htt also influences
NF-B activity, we used immortalized striatal cell lines obtained
from WT and HD KI mice (Gines et al., 2003). Using the reporter
with NF-B enhancer, no significant difference in basal NF-B
activity is observed between striatal cells from WT and HD KI
mice (Fig. 1D) (compare C lanes in WT and mutant). These data
are consistent with a recent report showing that inducible expres-
sion of full-length WT or mutant Htt in PC12 cells has no effect
on basal NF-B activation (Sugars et al., 2004). We therefore
asked whether WT and mutant cells respond differently to NF-
B-inducing agents. KI striatal cells display a stronger response
than WT cells to the NF-B-inducing cytokine IL-1 (Fig. 1D).
To verify that mutant Htt mediates the enhanced response to
IL-1, we used recombinant single chain intrabodies, which are
known to interfere with the function of mutant HDx1 (Khoshnan
et al., 2002) (see below). Two intrabodies, MW2 targeting the
expanded polyQ and MW7 recognizing the polyP motifs of
HDx1, reduce the IL-1-mediated NF-B activation in striatal
cells from KI mice (Fig. 1D). MW7 is somewhat more potent
than MW2 at inhibiting the effects of full-length mutant Htt on
NF-B.
Activated NF-B functions primarily in the nucleus, where it
regulates gene expression. To confirm the authenticity of the gene
reporter assays, we measured nuclear p65 binding to a consensus
NF-B oligonucleotide. Extracts from mutant Htt KI striatal cells
show elevated nuclear p65 binding in response to IL-1 treat-
ment when compared with the equivalent samples from WT stri-
atal cells (Fig. 2A). Specificity of binding was confirmed using a
mutated consensus NF-B oligonucleotide, which failed to show
p65 binding in this assay (data not shown). Thus, cells expressing
full-length mutant Htt respond more vigorously than cells with
WT Htt to IL-1-induced NF-B nuclear localization. We also
examined whether there is elevated nuclear NF-B in HD mouse
brains. Brain sections from 8-week-old R6/2 HD mice and age-
matched controls were stained with an antibody that recognizes
the p65 subunit. p65 is concentrated in the nucleus of a majority
of the NeuN-positive neurons in the cortex and striatum of HD
mice, whereas most of the neurons of the age-matched WT mice
contain cytoplasmic p65 (Fig. 2B,C). Thus, mutant Htt promotes
nuclear localization of NF-B in vivo as well as in cell culture.
Mutant Htt activates the IKK complex
Signal-induced phosphorylation of serine residues 32 and 36 of
IB, which is mediated by the IKK complex, is essential for the
ubiquitination and proteosome-mediated degradation of IB
(Ghosh and Karin, 2002). Because IB degradation is promoted
with mutant HDx1 induction, we examined whether the IKK
complex is activated by mutant HDx1 expression. Immunopre-
cipitated endogenous IKK complexes from extracts of control or
PC12 cells induced to express mutant HDx1 were analyzed for
their kinase activity by measuring phosphorylation of the recom-
binant substrate, GST-IB. The kinase activity of IKK from cells
expressing mutant HDx1 is significantly higher than that from
non-HDx1-induced cells (Fig. 3A). As expected, NGF treatment
also activates the IKK complex, and consistent with our gene
Figure 2. Mutant Htt promotes activation and nuclear localization of NF-B. A, Nuclear
proteins from control and IL-1-treated striatal cells from mutant Htt KI mice were tested for
binding to the oligonucleotide recognized by NF-B. Similar results showing that nuclear ex-
tracts from KI striatal cells have elevated p65 were found in three experiments. B, The nuclear
localization of the NF-B p65 subunit is elevated in HD transgenic brain. WT and R6/2 HD
transgenic mouse brains were stained with a rabbit anti-p65 antibody, and an anti-NeuN anti-
body was included to stain neurons. Toto–3 was used to stain nuclei. Representative confocal
micrographs of cortical regions of WT and R6/2 HD mice are presented. C, Quantification of
nuclear p65 staining shows the average percentage of positive neurons per microscopic field
from 16 brain sections of four animals each for WT and HD mice.
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reporter assay results, kinase activity appears to be elevated some-
what further when both NGF and HDx1 are present (4.1-fold
compared with 2.4- and 3.2-fold in the ecdysone and NGF-
treated cells, respectively). Expression of WT HDx1 has no effect
on IKK activity (data not shown).
To investigate whether IKK activation by mutant HDx1 also
occurs in vivo, we used two lines of HD transgenic mice, R6/2
(Davies et al., 1997) and a mutant Htt KI (Lin et al., 2001). IKK
complexes immunoprecipitated from striatal or cortical extracts
of WT and HD mice were assayed in vitro for IKK activity. Con-
sistent with the PC12 cell results, IKK activity is higher in com-
plexes isolated from striatal (9-fold) as well as cortical (3.8-fold)
extracts of 2-month-old R6/2 mice compared with age-matched
WT controls (Fig. 3B). With KI HD mice, a significant increase in
IKK activity is detected in the striatum at 1 year of age (4.8-fold
higher than WT) (Fig. 3C).
Because IKK activity is elevated in cell culture and in animal
models expressing mutant Htt, we tested whether HDx1 associ-
ates with IKK. Complexes isolated with an anti-IKK antibody
from PC12 cells were examined for the presence of HDx1 by
Western blotting. Soluble mutant HDx1 coprecipitates with IKK,
whereas minimal WT HDx1 is observed (Fig. 3D). Thus, IKK
physically forms a complex with mutant HDx1. This interaction
also occurs in the brain of HD mice. IKK
complexes isolated from brain extracts of
R6/2 mice contain soluble HDx1, which is
recognized by anti-Htt antibody (Fig. 3E).
Therefore, activation of IKK by mutant
HDx1 may be, in fact, the result of Htt
binding to the complex.
Mutant Htt interacts with IKK
The activity of the IKK complex is regu-
lated by IKK, a glutamine-rich non-
kinase subunit of the complex (Rothwarf
et al., 1998; Ghosh and Karin, 2002). A
homolog of IKK that participates in tu-
mor necrosis factor- receptor signaling
interacts with Htt in a yeast two-hybrid
assay (Hattula and Paranen, 2000). There-
fore, we asked whether the binding of mu-
tant HDx1 to the IKK complex is mediated
by IKK. A GST pull-down assay using
HDx1 fused to GST and [ 35S]methionine-
labeled IKK was used. The stringency of
the assay was such that there was no bind-
ing to GST alone. In vitro translated-IKK
preferentially binds to GST-HDx1 con-
taining expanded polyQ (Fig. 4A). Al-
though deletion of the C-terminal 119
amino acids of IKK (DC-IKK) has no
apparent effect on this binding, removal of
the first 134 amino acids (DN-IKK) di-
minishes binding to HDx1 (Fig. 4A). In-
terestingly, mutant HDx1 without its
polyP domains does not bind efficiently to
IKK (Fig. 4B). Although we cannot rule
out that the absence of proline may alter
the solubility of mutant HDx1 and thus
artifactually reduce binding to IKK, the
importance of the polyP domains is fur-
ther supported by antibody experiments.
We performed competition assays using
in vitro-translated, anti-Htt recombinant intrabodies (Khoshnan
et al., 2002). Coincubation of DC-IKK plus mutant HDx1 with
10-fold excess of intrabodies specific for polyQ (MW2) or polyP
(MW7) competes with binding of IKK to HDx1 (Fig. 4B).
Moreover, these intrabodies inhibit the HDx1-induced NF-B-
dependent gene expression in PC12 cells (Fig. 4C). Although
anti-polyQ intrabody has a modest inhibitory effect, anti-polyP
(MW7) significantly minimizes mutant HDx1-induced NF-B
activation. Thus, IKK binding to mutant HDx1 requires the
polyQ expansion and is influenced by the polyP domains. More-
over, this interaction likely plays a role in mutant HDx-1-induced
IKK and NF-B activation.
Inhibition of the NF-B pathway reduces HDx1-induced
toxicity in cell culture and brain slices
Because binding of mutant HDx1 to IKK influences IKK
activity and NF-B-mediated transcription, it was important
to determine whether IKK can modify the toxicity of mutant
HDx1. Confocal microscope examination of HEK-293 cells
expressing mutant HDx1 and IKK at an early time point
before widespread toxicity shows that full-length IKK pro-
motes aggregation of mutant HDx1 (Fig. 5A). Intracellular,
microscopically visible aggregates are apparent, and impor-
Figure 3. Mutant HDx1 activates the IKK complex. A, IKK complexes isolated from PC12 cells expressing mutant HDx1 have
elevated kinase activity. IKK complexes from control or cells expressing HDx1 were immunoprecipitated with anti-IKK antibody
coupled to protein-A beads. Kinase activity of the precipitated complexes was determined by incubation with GST-IB (the
N-terminal 62 amino acids) and [ 32P]ATP. Phosphorylated GST-IB was detected by SDS-PAGE and autoradiography (top
panels). KA, Kinase activity. The bottom panels show Western blots of duplicate samples for IKK. WB, Western blot. Similar
results were obtained when IKK complexes were isolated from striatal or cortical extracts of HD transgenic R6/2 mice ( B) or striatal
HD knock-in mice ( C). Bottom panels in B and C show Western blotting of precipitated IKK complexes with an anti-IKK antibody.
D, Mutant HDx1 coprecipitates with endogenous IKK complex. IKK complexes were immunoprecipitated with an anti-IKK anti-
body from control or PC12 cells induced to express HDx1 with 25 or 103 polyQ. IKKwas detected by Western blotting (bottom
blot). Similar complexes were examined for the presence of HDx1 (arrow) using an anti-Htt antibody (top blot). E, Mutant Htt
coimmunoprecipitates with IKK complexes isolated from R6/2 striatal extracts. IKK complexes were obtained with anti-IKK and
analyzed for mutant HDx1 as in A.
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tantly, some of these aggregates localize in the nucleus of
transfected cells. C-terminally truncated IKK, which also
binds to mutant HDx1 (Fig. 4 A), has a similar effect (data not
shown). On the other hand, DN-IKK, which does not bind to
mutant HDx1, has no apparent effect on HDx1 aggregation
(Fig. 5A). Thus, binding to IKK appears to promote aggrega-
tion and nuclear localization of mutant HDx1. Overexpres-
sion of full-length IKK appears to have little effect on toxicity
at 48 hr after transfection, however, because the overall num-
ber of cells killed by mutant HDx1 does not appear to change
(Fig. 5A). Toxicity was assessed by counting the number of
condensed GFP bodies at 48 hr after transfection, which are
remnants of dead cells (Khoshnan et al., 2002) (see Fig. 7B).
Importantly, DN-IKK strongly reduces the toxicity of mu-
tant HDx1 (Fig. 5A, graph). The effect of DN-IKK on mutant
HDx1 toxicity was confirmed by TUNEL assay. Compared
with cultures with or without full IKK, the number of
TUNEL cells is significantly reduced in cells cotransfected
with DN-IKK and mutant HDx1 (Fig. 5B). DN-IKK lacks
the binding domain essential for interaction with IKK and -
and interferes with IKK activity (May et al., 2000; Poyet et al.,
2000). DN-IKK also blocks basal and NGF-induced NF-B-
dependent gene expression by mutant HDx1 in inducible
PC12 cells (Fig. 5C). Therefore, inhibition of mutant HDx1
toxicity by DN-IKK may be mediated through blockage of
the NF-B pathway.
To extend these results to a more in vivo-like model, we used a
novel, acute, P7 rat brain slice assay. A biolistic method is used to
cotransfect neurons with three constructs: HDx1-CFP to visual-
ize HDx1 expression and associated neurodegeneration, YFP to
monitor the full morphology of transfected cells, and IKK or
DN-IKK. Individual, transfected MSNs are identified by loca-
tion and morphology and monitored daily for 7 d after transfec-
tion. Neuronal viability was quantified by counting the number
of CFP neurons in each slice at 7 d. Expression of mutant HDx1
leads to the formation of Htt aggregates (shown in cyan) 1–2 d
after transfection and to cell death within 4 –7 d. YFP apoptotic
bodies are seen initially, followed by complete loss of YFP fluo-
rescence. In contrast, neurons transfected with WT HDx1 do not
contain Htt inclusions and retain their normal dendritic struc-
ture (Fig. 6A). Coexpression of full-length IKKor DN-IKKhas
no obvious effect on MSNs expressing WT HDx1 (Fig. 6A,B).
Furthermore, expression of IKK has no significant effect on
neurodegeneration induced by expression of mutant HDx1 (Fig.
6A,B); however, the coexpression of DN-IKK with mutant
HDx1 is significantly neuroprotective (Fig. 6A,B). The neuro-
protective function of DN-IKK is essentially independent of
aggregate formation by mutant Htt, because rescued neurons still
contain Htt macro-aggregates (Fig. 6A). These brain slice results
indicate that DN-IKK also reduces the neurotoxicity of mutant
HDx1 in MSNs residing in a more intact, three-dimensional
setting.
Because ubiquitination of IB is a crucial step in liberating
NF-B, we predicted that blocking this step should have an effect
similar to that observed with DN-IKK. The E3-ubiquitin ligase
TrCP specifically promotes degradation of IB (Spencer et al.,
1999). A dominant-negative form of TrCP (F-TrCP), which
has been shown to block degradation of phosphorylated IBs,
was cotransfected with the NF-B reporter in PC12 cells. Expres-
sion of F-TrCP abolishes basal and mutant HDx1-induced
NF-B activity (Fig. 7A). As predicted, F-TrCP expression
also blocks the toxicity of mutant HDx1 in cultured cells (Fig.
7B,C). Cells expressing F-TrCP and mutant HDx1 remain
intact, whereas cells transfected with mutant HDx1 and control
vector become condensed and eventually detach from the culture
dish (Fig. 7B, arrow). Moreover, expression of F-TrCP in the
brain slice assays significantly reduces the toxicity of mutant
HDx1 in MSNs (Fig. 7D). WT-TrCP does not influence the
Figure 4. Mutant Htt directly interacts with IKK. A, Full-length (F) and C-terminal-
truncated IKK (DC) bind to mutant HDx1 (51polyQ). IKK constructs were expressed by in vitro
translation in the presence of [ 35S]methionine (middle left panel). HDx1 with 20 (PQ20) or 51
(PQ51) polyQ fused to GST was expressed in E. coli and captured on GST beads (middle right
panel). Each in vitro-translated IKK product was incubated with each GST-HDx1. The beads
were washed, and bound IKKwas detected by SDS-PAGE followed by autoradiography (bot-
tom panel). B, Binding of IKK to mutant HDx1 requires the Htt polyQ and polyP domains.
Recombinant anti-Htt antibodies MW2 and MW7 were translated in vitro and tested for binding
to GST-HDx1 (lanes MW2 and MW7). rAb, Recombinant antibody band. Addition of 10-fold
excess of MW2 or MW7 to the reactions competes for binding of GST-HDx1 to IKK (compare
intensity of lanes MW2DC and MW7DC with lane DC). C, Expression of anti-HDx1 recom-
binant antibodies reduces NF-B-dependent gene expression. PC12 cells expressing mutant
HDx1 were transfected using lipofectamine with NF-B reporter and the indicated Flag-tagged,
recombinant, anti-Htt intrabody and -gal plasmids. Twenty-four hours after transfection,
cells were treated with ecdysone. Samples were processed as in Figure 1 A. Transfections were
normalized to-gal units from control, noninduced HDx1. Results are shown as relative lucif-
erase units and are representative of at least three independent experiments. Data points are
the average of triplicate measurements. Expression of recombinant anti-Htt intrabody was
confirmed by Western blotting (inset).
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toxicity of mutant HDx1 in MSNs (Fig. 7D). Collectively, these
data show that blocking IKK activity or degradation of IB, both
of which result in inhibition of NF-B, can reduce the toxicity of
mutant HDx1.
Discussion
Transcriptional dysregulation has been
implicated in HD pathology, and mutant
Htt can sequester transcription factors
and reduce gene expression (Cattaneo et
al., 2001; Ross, 2002; Yu et al., 2002) or
increase the transcriptional activity of spe-
cific signaling pathways (Yohrling et al.,
2003; Obrietan et al., 2004). We find that
soluble mutant Htt interacts with the IKK
complex, promotes phosphorylation and
degradation of IB, and subsequently
enhances NF-B activity. Results from the
HD cell culture model are supported by
findings that IKK complexes from striatal
and cortical extracts of HD transgenic
mice also have elevated kinase activity,
and activated NF-B is concentrated in
the nuclei of cortical and striatal neurons
of HD transgenic mice. Most importantly,
interference with the NF-B pathway by
expression of DN-IKK or F-TrCP re-
duces the toxicity of mutant Htt in cell
culture and protects striatal MSNs in a
brain slice model of HD. These findings
implicate the NF-B pathway in the neu-
rotoxicity of mutant Htt.
Current paradigms of HD pathology in-
clude increased sensitivity to NMDA-
mediated excitotoxicity and activation of
caspases (Cepeda et al., 2001; Zeron et al.,
2002). Although the signaling cascades that
contribute to enhanced sensitivity of striatal
neurons in HD are poorly understood, de-
rangement of Ca2 efflux from the endo-
plasmic reticulum by binding of mutant Htt
to the inositol (1,4,5)-triphosphate receptor
may be a contributing factor (Tang et al.,
2003). In neurons and other cell types, ele-
vated Ca2 influx is a major activator of the
IKK complex and subsequently NF-B (Lil-
ienbaum and Israel, 2003). We find that stri-
atal cells from HD KI mice expressing full-
length mutant Htt respond more vigorously
to IL-1-induced NF-B activation (Fig.
1C,D). IL-1can increase NMDA-mediated
neurotoxicity by activation of tyrosine ki-
nases and subsequent phosphorylation of
NMDA receptor (Viviani et al., 2003). It is
relevant that brain lysates of R6/2 HD mice
have significantly higher levels of IL-1 than
WT controls (Ona et al., 1999). In addition,
inhibitors of IL-1 converting enzymes are
effective against the toxicity of mutant Htt in
tissue culture and animal models (Chen et
al., 2000). Mutant HDx1 also enhances
NGF-induced IKK and NF-B activation
(Figs. 1A, 3A). Therefore, a potential ac-
quired function of mutant Htt is to intensify
the effects of extracellular signals that function thorough the IKK
complex.
A novel aspect of the present data is the mechanism by which
Figure 5. DN-IKK reduces the toxicity of mutant HDx1. A, IKKpromotes aggregation and nuclear localization of Htt. HEK-293
cells were transfected with mutant HDx1-EGFP plus the indicated IKK constructs using lipofectamine and incubated for 16 hr. Cells
were fixed and stained for IKKwith anti-HA antibody (red), and cell nuclei were stained with Toto-3. Slides were examined with
a confocal microscope. Conditions were such that mutant HDx1 did not cause aggregation on its own. The graph shows the average
number of apoptotic bodies per microscopic field for each sample evaluated 2 d after transfection. Data are average counts of
apoptotic cells from three experiments and six random microscope fields for each sample. B, DN-IKK expression reduces the
toxicity of mutant HDx1. HEK-293 cells were transfected as in A for 16 hr. Apoptotic cells were identified by TUNEL assay as
described in Materials and Methods. The top panel shows representative microscopic fields with TUNEL cells in each sample. The
graph shows the average number of TUNEL cells in 16 microscopic fields from three experiments. C, DN-IKK blocks HDx1-
induced NF-B activation. Mutant HDx1 cells were cotransfected with NF-B reporter and HA-tagged DN-IKK and-gal plas-
mids and processed as described in Figure 1 A. Transfections were normalized to -gal units from control, noninduced HDx1.
Results are shown as relative luciferase units and are representative of at least three independent experiments. Data points are the
average of triplicate measurements. Expression of DN-IKKwas confirmed by Western blotting using an anti-HA antibody (inset).
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mutant Htt stimulates NF-B. Mutant Htt
activates the IKK complex both in cell cul-
ture and in mouse models of HD (Fig. 3).
Our evidence indicates that activation of
the IKK complex is likely caused by bind-
ing of mutant HDx1 to IKK. Optimal
HDx1 binding requires interaction with
the first N-terminal 134 amino acids of
IKK (Fig. 4), a domain that is essential
for interaction with IKK and IKK, two
catalytic units of the IKK complex (May et
al., 2000). It is plausible that mutant Htt
binding to this region of IKK triggers oli-
gomerization, a step that is essential for
signal-induced IKK activation (Poyet et
al., 2000; Tegethoff et al., 2003). It cannot
be ruled out, however, that Htt–IKK
binding mediates IKK interaction with
other regulators responsible for phos-
phorylation and activation of the complex
(Ghosh and Karin, 2002). Interaction of
Htt with IKK requires polyQ expansion
as well as the proline-rich motifs of HDx1.
A similar scenario has been reported for
the interaction of CBP and several WW-
rich motif proteins implicated in HD pa-
thology (Faber et al., 1998; Steffan et al.,
2001). We find that recombinant intra-
bodies targeted to the polyP or polyQ mo-
tifs can inhibit Htt–IKK binding and NF-
B-mediated gene expression. The anti-
polyP intrabody, which is more potent,
also reduces mutant HDx1 aggregation
and protects cells from the toxicity of mu-
tant Htt (Khoshnan et al., 2002). There-
fore, the toxicity of mutant HDx1 may be
reduced by interference with its binding to
the IKK complex.
Expression of IKK also promotes
aggregation and nuclear localization of
mutant HDx1 before the widespread on-
set of toxicity in cell culture. Consider-
ing the propensity of both mutant HDx1
and IKK to oligomerize, their interaction may lead to en-
hanced aggregation of both proteins. Although the role of
macro-inclusions in HD pathology is controversial, nuclear
localization is thought to be a determinant of pathology (Sau-
dou et al., 1998). IKK, which enters the nucleus (Anest et al.,
2003; Yamamoto et al., 2003), is associated with nuclear HDx1
aggregates (Fig. 5A). Thus, IKK-induced nuclear localization
of mutant HDx1 may influence Htt function. Conversely,
binding of mutant Htt to the IKK complex may regulate nu-
clear IKK function.
The inhibition of mutant HDx1 toxicity by DN-IKK in cell
culture and in MSNs is likely attributable to deregulation of IKK
and subsequent inhibition of NF-B activity. We cannot rule out
the possibility, however, that DN-IKK inhibits mutant HDx1
toxicity by an as yet unknown mechanism. Because both IKK
and mutant Htt interact with CBP and regulate CBP-mediated
gene expression (Nucifora et al., 2001; Verma et al., 2004), bind-
ing of IKK to mutant Htt could influence CBP sequestration
and Htt toxicity; however, the similar effects of DN-IKK and
F-TrCP in blocking cell death in cell culture and in MSNs
support a role for NF-B in mutant Htt toxicity. Because IKK
activity and TrCP are also essential for processing of the NF-B
precursors p100 and p105 to the p52 and p50 subunits, respec-
tively, DN-IKK andF-TrCP may also interfere with the gen-
eration of active NF-B complexes and reduce the available
NF-B pool (Xiao et al., 2001; Fong and Sun, 2002).
Mutant Htt-induced activation of IKK can influence other sig-
naling pathways that intersect with the NF-B pathway. For in-
stance, Akt, a modulator of IKK activity and a substrate for NF-B,
regulates the toxicity of mutant Htt and ataxin-1 (Humbert et al.,
2002; Meng et al., 2002; Chen et al., 2003; Emamian et al., 2003). In
addition, the wingless and NF-B pathways share the E3-TrCP
ubiquitin ligase, which is essential for degradation of both IB and
-catenin (Winston et al., 1999). Thus, the inhibition of mutant
HDx1-induced toxicity by F-TrCP may also be mediated by a
reduction in -catenin turnover. Mutant Htt can either stabilize or
promote degradation of-catenin (Carmichael et al., 2002; Gines et
al., 2003). Mutant Htt also induces expression of cyclin D1, which is
downstream of -catenin (Gines et al., 2003), whereas signal-
induced IKK phosphorylation of -catenin promotes cyclin D1 ex-
Figure 6. DN-IKK protects striatal MSNs against mutant HDx1. A, Living MSNs can be monitored for morphology and Htt
expression. Coronal brain slices were cotransfected by biolistic procedures with HDx1–23Q or HDx1–148 and IKK or DN-IKK.
The morphology of transfected cells was monitored by YFP fluorescence (yellow), and Htt expression was monitored by CFP
fluorescence (cyan). B, Expression of DN-IKK is neuroprotective for MSNs in brain slices. MSN survival was scored 3 d after
transfection. Each experiment involved 3–12 transfected brain slices per condition, and the data are means from six independent
experiments for each condition.
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pression (Albanese et al., 2003). Thus, the interaction between mu-
tant Htt and the IKK complex can influence a number of signaling
pathways and represents an interesting target for intervention in
polyglutamine-induced toxicity.
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